一名溃疡性结肠炎患者发生英夫利昔单抗诱导的免疫性血小板减少性紫癜
Infliximab-Induced Immune Thrombocytopenic Purpura in an Ulcerative Colitis Patient.
作者信息
Lai Mark, Phan Timothy, Niewiadomski Ola, Ding Nik
机构信息
Department of Gastroenterology, St Vincent's Hospital, Melbourne, VIC, Australia.
Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia.
出版信息
Case Rep Gastroenterol. 2025 Jun 4;19(1):392-396. doi: 10.1159/000545922. eCollection 2025 Jan-Dec.
INTRODUCTION
Ulcerative colitis is a chronic inflammatory disease affecting the colon. Anti-tumor necrosis factor-alpha drugs are a cornerstone of management in ulcerative colitis both in induction and maintenance of remission. Thrombocytopenia is a rare side effect of these drugs.
CASE PRESENTATION
We present a case of infliximab-induced immune thrombocytopenic purpura in a 34-year-old female ulcerative colitis patient.
CONCLUSION
Infliximab can be a cause of drug-induced immune-related thrombocytopenia and patient's platelet counts should be regularly monitored. In patients with severe thrombocytopenia and having been recently commenced on infliximab, prompt referral to hematology specialty is essential.
引言
溃疡性结肠炎是一种影响结肠的慢性炎症性疾病。抗肿瘤坏死因子-α药物是溃疡性结肠炎诱导缓解和维持缓解治疗的基石。血小板减少是这些药物罕见的副作用。
病例报告
我们报告一例34岁女性溃疡性结肠炎患者因英夫利昔单抗诱发免疫性血小板减少性紫癜的病例。
结论
英夫利昔单抗可能导致药物性免疫相关血小板减少，应定期监测患者的血小板计数。对于近期开始使用英夫利昔单抗且出现严重血小板减少的患者，及时转诊至血液科专科至关重要。
Zotero 插件